News & Media
Stay up to date with the latest press releases, media coverage, and company updates from Vyome Holdings.
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
Nov 25, 2025
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Nov 18, 2025
Vyome Holdings Announces Results of Annual Shareholder Meeting
Nov 4, 2025
Vyome Holdings Acquires MIT AI Spinout Oculo Health
Sep 29, 2025
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
Sep 17, 2025
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
Sep 9, 2025
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW)
Sep 4, 2025
Vyome Announces Strategic Review of Livechain (OTCID: LICH)
Aug 18, 2025
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
Aug 15, 2025
Vyome Closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
Aug 14, 2025
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
Aug 13, 2025
Vyome Announces New Board of Directors with Deep MIT and AI Ties
Aug 12, 2025
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
Aug 7, 2025
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
Jul 24, 2025
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
Jul 21, 2025
ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
Jun 26, 2025
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
Apr 7, 2025
Vyome Therapeutics Presents Positive Data from Early Analysis of a Phase 2 Study of VT-1953 in Malignant Fungating Wound
Jan 22, 2025
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
Jan 13, 2025
Vyome Therapeutics featured on Yahoo! Finance
Jan 9, 2025
Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol 'HIND'
Jul 9, 2024
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
Jul 9, 2024
